HomeCompareAREVF vs JNJ

AREVF vs JNJ: Dividend Comparison 2026

AREVF yields 400000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AREVF wins by $5.011119029548644e+32M in total portfolio value
10 years
AREVF
AREVF
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full AREVF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AREVF vs JNJ

📍 AREVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAREVFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AREVF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AREVF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AREVF
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, AREVF beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AREVF + JNJ for your $10,000?

AREVF: 50%JNJ: 50%
100% JNJ50/50100% AREVF
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AREVF
No analyst data
Altman Z
-128.2
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AREVF buys
0
JNJ buys
0
No recent congressional trades found for AREVF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAREVFJNJ
Forward yield400000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$5.011119029548644e+32M$30.3K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$5.010957816668433e+32M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AREVF vs JNJ ($10,000, DRIP)

YearAREVF PortfolioAREVF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$40,010,700$40,000,000.00$10,592$272.30+$40.00MAREVF
2$149,615,521,729$149,572,710,280.37$11,289$357.73+$149615.51MAREVF
3$522,880,052,725,200$522,719,964,116,949.25$12,123$472.89+$522880052.71MAREVF
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$13,141$629.86+$1707862989289.03MAREVF
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$14,408$846.81+$5213509402845684.00MAREVF
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$16,021$1,151.60+$14874219058409543680.00MAREVF
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$18,122$1,588.22+$3.966119623405075e+22MAREVF
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$20,930$2,228.20+$9.88384363503273e+25MAREVF
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$24,792$3,191.91+$2.302052364743449e+29MAREVF
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$30,274$4,689.40+$5.011119029548644e+32MAREVF

AREVF vs JNJ: Complete Analysis 2026

AREVFStock

AREV Life Sciences Global Corp., an integrated life science discovery company, produces and sells functional ingredients in Canada. The company's CBD-infused products, include Canna-Mulsion and NaturVax, anti- viral supplements; NaturRelax, a natural Sleep Aid; Natur Relief, an anti-inflator and pain relief product; and white label cannabis products, as well as a range of THC products, and cannabis skincare products and medicinal oils and edibles. Its ingredients are used in products that are targeted for sale in the natural health, medical, functional food, nutraceutical, sports nutrition, and bioceutical markets. In addition, the company's products address the areas of health, which include sleep deprivation, insomnia, anxiety, pain, and inflammatory conditions, as well as other specific ailments. Further, it offers nutraceutical product formulations under the Bare brand name; and ready-to-use therapeutic food products under the SUS-TAINN name. The company was formerly known as AREV NanoTec Brands Inc. and changed its name to AREV Life Sciences Global Corp. in August 2021. AREV Life Sciences Global Corp. was incorporated in 2005 and is based in Coquitlam, Canada.

Full AREVF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AREVF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AREVF vs SCHDAREVF vs JEPIAREVF vs OAREVF vs KOAREVF vs MAINAREVF vs ABBVAREVF vs MRKAREVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.